Frontier Medicines Corporation
151 Oyster Point Blvd.
South San Francisco
4 articles with Frontier Medicines Corporation
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies
South San Francisco-based Frontier Medicines today announced three key additions to its executive team with the hiring of Chief Scientific Officer Kevin Webster, Chief Technology Officer Johannes Hermann and Head of Degrader Technologies James Winkler.
Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease
Frontier Medicines today announced the closing of a Series A Preferred Stock financing round of $67 million led by Deerfield Management, Droia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors.